What FDA requires for bispecific antibody approval that a conventional monoclonal antibody does not

Bispecific antibodies are reviewed by CDER and CBER inside the same biologics framework that governs conventional monoclonal antibodies (mAbs). FDA's position is explicit: many aspects of a bispecific program mirror standard mAb development ¹². The differences are not a separate regulatory pathway, they are a set of additional questions layered onto the mAb template because a single molecule now binds two targets, can cross-link cells, and adopts non-native structures. The governing document is the FDA guidance Bispecific Antibody Development Programs (issued May 2021), which should be read alongside the therapeutic-protein immunogenicity guidances and, for T-cell engagers, the newer dose-selection guidance ¹¹⁴⁴³.

Below are the areas where a bispecific submission carries requirements a conventional mAb does not.

A documented rationale for the bispecific format itself

Unlike a single-target mAb, a bispecific must justify why it exists as one molecule. FDA expects a scientific rationale for the choice of a bispecific, covering the target(s), the mechanism(s) of action, and the expected safety or efficacy advantage over the corresponding monospecific products ¹². Because the value proposition often rests on engaging two targets at the same time, developers are asked to address whether simultaneous engagement is actually required, the affinity and on/off rates of each binding arm, and any expected synergy between the two arms ¹. Supporting evidence can come from clinical, animal, or in vitro data ¹. This "why two targets" burden has no analogue in a conventional mAb program.

Quality and CMC: mispairing, homodimers, and two-armed functional characterization

A conventional mAb is a single, correctly paired structure. A bispecific can be built in many formats, and the assembly process creates product-related species that do not occur with a standard antibody. FDA directs that bispecifics still be characterized and manufactured using standard mAb practices, but flags additional critical quality attributes ⁴:

• Product-related impurities unique to the format. Beyond the usual aggregates and fragments, FDA calls out homodimers and other mispaired species as attributes that must be characterized and controlled ⁴. Chain mispairing is a defining CMC problem for bispecifics and drives the control strategy.
• Homodimer content tied to a safety signal. FDA specifically recommends assessing the relative amount of homodimers, especially for effector-cell-engaging constructs, because anti-CD3 (or other effector-arm) homodimers can trigger cytokine release ⁴. Here a manufacturing attribute is linked directly to clinical toxicity.
• Per-arm functional characterization. Quality attributes to be studied include antigen specificity, affinity and on/off rates, avidity, potency, stability, and half-life, evaluated with each target in mind ⁴. Potency and pharmacodynamic assays must account for binding to both targets, and more than one assay may be needed to measure the biologically relevant forms ²⁶.
• Construct selection. FDA suggests early in vitro studies to select the expression construct with optimal affinity and stability, and notes that novel structures can increase immunogenicity ⁴.

The net effect is a more complex analytical package: FDA characterizes bispecifics as posing challenges of "complex structural and functional characterization" that a monospecific antibody does not raise ²⁴.

Nonclinical: similar scope, but two-target biology and MABEL dosing

The nonclinical program is broadly similar to a single-target mAb in scope and species selection ⁴. The bispecific-specific overlays are:

• Two-target expression and specificity. Sponsors should consider the expression profile and specificity of each target in the nonclinical models chosen, so the toxicology assessment reflects both arms ⁵. Finding a single species that is pharmacologically relevant to both targets is often harder than for a monospecific antibody.
• No mandatory head-to-head vs the monospecific. FDA states a comparative nonclinical safety assessment against the monospecific product(s) will likely not be recommended ⁵.
• Pharmacology to support the rationale. In vitro and in vivo studies can substantiate the design rationale by showing additive or synergistic efficacy, efficacy driven by simultaneous cross-linking, or the expected immune activation, and can inform the first-in-human dose ⁵.
• MABEL for agonists and immune activators. For agonistic bispecifics, FDA recommends considering a minimal anticipated biological effect level (MABEL) approach to set the initial dose rather than a NOAEL-based dose ⁵. MABEL is a dose expected to produce a minimal biological effect in humans, estimated from pharmacologic activity and receptor-binding data in human cells integrated with PK; for high-risk products FDA says to choose the most conservative (lowest) starting dose when methods disagree ⁴⁶⁴⁷. A June 2026 FDA guidance adds a quantitative systems pharmacology (QSP)-based approach to deriving the MABEL dose for first-in-human trials ⁴³⁵⁶.

Clinical pharmacology and dosing: PK/PD for two domains, and step-up dosing

Clinical pharmacology studies resemble those for any therapeutic protein, but the analytics must be doubled up ⁵:

• Multiple, validated PK/PD assays. Because a bispecific can circulate as a mixture of biologically active and inactive forms, sponsors must identify the forms most relevant to PK/PD and develop validated assays to measure them, sometimes needing more than one assay ⁵. With multiple functional domains, multiple PD assays may be appropriate ⁶.
• Dose selection discussed with FDA. FDA specifically asks sponsors to discuss dose selection with the relevant clinical review division ⁵, reflecting the narrower therapeutic window of cell-engaging constructs.
• Healthy-volunteer caution. FDA notes healthy volunteers may not be appropriate for the initial clinical trial of a given bispecific because of potential immunogenicity and toxicity ⁵, a departure from many conventional first-in-human designs.

In practice, cell-engaging bispecifics are approved with step-up (priming) dose schedules rather than the flat dosing typical of conventional mAbs. Approved products including mosunetuzumab (Lunsumio), teclistamab (Tecvayli), glofitamab (Columvi), elranatamab (Elrexfio), and linvoseltamab (Lynozyfic) all use escalating step-up dosing to blunt cytokine release before reaching the treatment dose ^7269807670.

Immunogenicity: domain-specific assessment

For a conventional mAb, a single anti-drug antibody strategy is usually sufficient. For a bispecific, FDA reasons that an immune response against one domain may inhibit that domain's function while leaving the others intact, so it may be appropriate to develop multiple assays to measure immune responses to the different domains ⁶. The FDA immunogenicity guidance reinforces this: for multi-domain products such as bispecific antibodies, a general assessment of domain specificity may be needed and multiple assays may be required ¹⁴¹⁸.

Clinical safety and labeling: boxed warnings, hospitalization, and REMS

The clinical-safety consequences of engaging effector cells produce labeling and post-market controls that conventional mAbs rarely carry. Across approved T-cell-engaging bispecifics, FDA has required:

• Boxed warnings for cytokine release syndrome (CRS) and neurologic toxicity, including ICANS. Teclistamab, elranatamab, and linvoseltamab all carry boxed warnings for both CRS and neurologic toxicity/ICANS; glofitamab and mosunetuzumab carry CRS boxed warnings with neurologic-toxicity warnings ^7376718072.
• Mandatory premedication before dosing to reduce CRS ^7269807670.
• Inpatient monitoring around step-up doses. Labels specify hospitalization windows tied to the step-up schedule, for example 48 hours after step-up doses for teclistamab, 48 hours after the first and 24 hours after the second step-up dose for elranatamab, and 24-hour windows for linvoseltamab and glofitamab ^69828380.
• REMS programs. Products such as teclistamab, talquetamab, and elranatamab were approved with Risk Evaluation and Mitigation Strategies to manage CRS and neurologic toxicity ⁷⁵⁷⁹⁸².

These features flow from mechanism, not from statute, but they are a predictable regulatory expectation for cell-engaging bispecifics and are not standard for conventional antibodies.

Comparator and benefit-risk expectations

FDA asks sponsors to define the overall benefit-risk profile ⁶. Bispecific trials often use standard of care or placebo as the comparator, as any program would, but FDA adds a bispecific-specific consideration: if an approved monospecific product already targets the same antigen(s), a trial comparing the bispecific against that monospecific may inform benefit-risk, and FDA may request such a comparison in some cases ⁶. That expectation directly tests the two-target rationale the program is built on.

Bottom line

A bispecific antibody is not approved through a different door than a monoclonal antibody, but the reviewer applies the mAb template plus a defined overlay: justify the bispecific format, characterize and control mispaired and homodimeric species, run two-target functional and PK/PD analytics, use MABEL-based (increasingly QSP-informed) starting doses for effector engagers, assess immunogenicity domain by domain, and expect CRS/ICANS boxed warnings, step-up dosing, inpatient monitoring, and possibly a REMS in labeling ¹⁴⁵⁶⁴³. The consistent theme across every one of these areas is that binding two targets in one molecule introduces structural, pharmacologic, and safety questions a single-target antibody never raises.